SCHEMBL944099

SCHEMBL944099

CS(=O)(=O)c1ccccc1S

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 1/20 0.40
LOX P28300 1/20 0.37
DRD2 P14416 1/20 0.36
HSD11B1 P28845 1/20 0.36
JAK2 O60674 1/20 0.36
JAK3 P52333 1/20 0.36
PTK2 Q05397 1/20 0.36
GAA P10253 1/20 0.36
ALOX5AP P20292 1/20 0.35
FEN1 P39748 1/20 0.35
ADRA2A P08913 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA4 P22748 2/20 0.34
CA6 P23280 2/20 0.34
MAPT P10636 2/20 0.34
CA12 O43570 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29644921 1.00 BCAT2 (0.40) BCAT2LOXDRD2HSD11B1JAK2
SCHEMBL7269139 0.98 BCAT2 (0.39) BCAT2LOXDRD2HSD11B1JAK2
SCHEMBL7262689 0.84 BCAT2 (0.33) BCAT2LOXJAK2JAK3PTK2
SCHEMBL8106699 0.81 LOX (0.47) BCAT2LOXDRD2HSD11B1GAA
SCHEMBL3279998 0.79 GAA (0.50) GAACA1CA2CA4CA6
SCHEMBL30948577 0.79 GAA (0.50) GAACA1CA2CA4CA6
SCHEMBL27996869 0.76 PSIP1 (0.48) HSD11B1GAAALOX5APFEN1ADRA2A
SCHEMBL4613245 0.75 ALDH1A1 (0.44) GAACA1CA2CA4CA6
SCHEMBL1048970 0.75 TSHR (0.44) GAACA1CA2CA4CA6
SCHEMBL1806991 0.75 CA2 (0.56) GAACA1CA2CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114728935-A SHP2 inhibitor IRBM股份公司 2022-07-08 CN disclosed
EP-2563123-B1 NOVEL BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2018-04-25 EP disclosed
US-8987516-B2 Process for producing arylsulfur pentafluorides UBE INDUSTRIES, LTD. (JP) 2015-03-24 US disclosed
CN-101663268-B Method for preparing aryl sulfur pentafluoride UBE INDUSTRIES 2014-12-24 CN disclosed
EP-2468722-B1 Process for producing arylsulfur halotetrafluorides UBE INDUSTRIES (JP) 2014-10-01 EP disclosed
EP-2468721-B1 Process for producing arylsulfur pentafluorides UBE INDUSTRIES (JP) 2014-02-26 EP disclosed
US-20140018537-A1 GPR119 AGONIST NIPPON CHEMIPHAR CO., LTD. (JP) 2014-01-16 US disclosed
EP-2468720-B1 Process for producing arylsulfur pentafluorides UBE INDUSTRIES (JP) 2013-11-27 EP disclosed
EP-2468719-B1 Process for producing arylsulfur pentafluorides UBE INDUSTRIES (JP) 2013-10-16 EP disclosed
US-8536176-B2 GPR119 agonist NIPPON CHEMIPHAR CO., LTD. (JP) 2013-09-17 US disclosed
WO-2004106302-A1 NOVEL SUBSTITUTED 3-SULFUR INDOLES ASTRAZENECA AB (SE) 2004-12-09 WO disclosed
US-20030220524-A1 Sulfur containing compounds LANGLER RICHARD FRANCIS (CA) 2003-11-27 US disclosed
EP-1259482-A2 SULFUR CONTAINING COMPOUNDS University Health Network (CA) 2002-11-27 EP disclosed
WO-2001062668-A2 SULFUR CONTAINING COMPOUNDS UNIVERSITY HEALTH NETWORK (CA) 2001-08-30 WO disclosed
EP-0451007-B1 Sulphonylphenyl-beta-D-thioxylosides, process for their preparation and their use in therapy FOURNIER IND & SANTE (FR) 1995-11-08 EP disclosed
US-5296579-A From (hydro)sulfide, polyhalogenated aromatic compound and a mercaptan PHILLIPS PETROLEUM COMPANY (US) 1994-03-22 US disclosed
US-5100913-A Venous antithrombotics FOURNIER INDUSTRIE ET SANTE (FR) 1992-03-31 US disclosed
EP-0451007-A1 Sulphonylphenyl-beta-D-thioxylosides, process for their preparation and their use in therapy FOURNIER INDUSTRIE ET SANTE (FR) 1991-10-09 EP disclosed
US-4192829-A INSECTICIDES, MITICIDES, NEMATOCIDES EXXON RESEARCH & ENGINEERING CO. (US) 1980-03-11 US disclosed
US-4075332-A Pesticidal O,S'-dialkyl S-hydrocarbylthioalkyl dithiophosphates and oxidized derivatives thereof EXXON RESEARCH & ENGINEERING CO. (US) 1978-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220524-A1 Sulfur containing compounds SQOR, MCL1, NDUFS5 BCAT2 1844/4885LOX 2621/4885DRD2 4248/4885
US-20140018537-A1 GPR119 AGONIST GPR119, GPR27, GPR52 BCAT2 1831/4885LOX 3740/4885DRD2 182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.